Downward price pressure on Heron Therapeutics (HRTX) stock has historically been driven by a combination of factors typical of micro-cap biotechnology firms, including cash burn concerns, dilution risks from capital-raising activities, and commercialization ramp-up challenges for its flagship pharmaceutical products. Additionally, broader market rotations away from speculative small-cap equities and mixed quarterly revenue reports can trigger heavy selling pressure from risk-averse institutional and retail investors alike.